Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the PROTECT III Study
Authors' conclusion
In this study, rates of 90-day MACCE compared favorably to prior cohorts of HRPCI patients and there was no significant sex differences.
Study context
- Population
- Patients undergoing Impella-supported high-risk PCI, March 2017 to March 202027% female
- Participants
- 1,237 patients
- Comparison
- Female vs male patients undergoing Impella-supported high-risk PCI
- Primary endpoint
- MACCE:
- All-cause death
- MI
- Stroke/TIA
- Repeat revascularization
- Follow-up
- 90 days
Methodological detailsprospective, multicentre, propensity matching, multivariable regression
- Prospective
- Multicentre
- Propensity matching
- Multivariable regression
Primary result
As reported in the abstract
90-day MACCE
- No sex differences in 90-day major adverse cardiac and cerebrovascular events (MACCE)
Further findings
Presentation with acute MI
| Outcome | Female | Male |
|---|---|---|
| Drop in SYNTAX score post-procedure | −22.6 | −21.0 |
- Presentation with acute MI: P = 0.02
- Drop in SYNTAX score post-procedure: P = 0.04
Safety
Immediate PCI-related coronary complications
- Immediate PCI-related coronary complications: P = 0.004
Immediate PCI-related coronary complications
- Only safety or clinical outcome significantly different by sex after propensity matching and multivariable regression
Vascular complications requiring surgery, major bleeding, acute limb ischemia
- No sex differences
Original publication
Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the PROTECT III Study. JACC Cardiovasc Interv. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →